PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF COMBINATION RANIBIZUMAB (LUCENTIS) AND BROMFENAC (XIBROM) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Pilot Study
The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
PURPOSE: To evaluate whether bromfenac eyedrops and ranibizumab intravitreal injections would provide added efficacy over ranibizumab alone. METHODS: This was a single-site, multiinvestigator, prospective, open-label, interventional, Phase II study of patients with new or recurrent exudative/neovascular age-related macular degeneration. Thirty eyes were enrolled consecutively and were randomized in a ratio of 2:1 to combination therapy with intravitreal ranibizumab and topical bromfenac, and ranibizumab alone. All patients received ranibizumab monthly therapy for 4 months then as needed monthly in accordance with standard of care. Patients receiving bromfenac self-administered 1 drop twice a day for 12 months. Patients were followed for 12 months. RESULTS: There were no safety concerns with the combination therapy. No statistically significant differences were identified in Early Treatment Diabetic Retinopathy Study best-corrected visual acuity or the number of injections required. However, the mean 12-month change in central macular thickness in the combination group was -81.56 μm while in the ranibizumab group alone the change was -42.50 μm (P = 0.03). The proportion of eyes experiencing a decrease in CMT of 50 μm or more was also significantly higher in those receiving combination therapy (P = 0.046). CONCLUSION: This pilot study is the first to prospectively identify a biologic signal that may indicate combination therapy with an easily administered well-tolerated eyedrop and ranibizumab is efficacious for the treatment of neovascular age-related macular degeneration. Further studies are warranted to validate this finding.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Bird, A. C., Bressler, N. M., Bressler, S. B., Chisholm, I. H., Coscas, G., Davis, M. D., de Jong, P. T. V. M., Klaver, C. C. W., Klein, B. E. K., Klein, R., et al. (1995) · Survey of Ophthalmology · doi:10.1016/s0039-6257(05)80092-x · Cited by 1,926 · cited 1×
“result of untreated disease is frequently marked by loss of central vision.(3) Undoubtedly, vascular endothelial growth factor (VEGF) is a major orchestrator of this process, and a considerable therapeutic benefit has been achieved in both AMD and diabetic retinopathy from regular intravitreal humanized monoclonal ant…”
BackgroundBrown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849 · cited 1×
“Undoubtedly, vascular endothelial growth factor (VEGF) is a major orchestrator of this process, and a considerable therapeutic benefit has been achieved in both AMD and diabetic retinopathy from regular intravitreal humanized monoclonal anti-VEGF antibody injections, such as ranibizumab.(4,5) Although a significant”
Background(2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.06.052 · Cited by 614
(2000) · CrossRef Listing of Deleted DOIs · doi:10.1016/j.ohc.2006.05.009 · Cited by 299 · cited 1×
“Undoubtedly, vascular endothelial growth factor (VEGF) is a major orchestrator of this process, and a considerable therapeutic benefit has been achieved in both AMD and diabetic retinopathy from regular intravitreal humanized monoclonal anti-VEGF antibody injections, such as ranibizumab.(4,5) Although a significant”
BackgroundChang, T. S. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.11.1460 · Cited by 239
Photodynamic Therapy for Angioid Streaks
Browning, A. C., Amoaku, W. M. K., Chung, A. K. K., Ghanchi, F., Harding, S. P., Musadiq, M., Yang, Y. C., & Talks, J. S. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.03.057 · Cited by 97
Inflammation and the pathogenesis of age-related macular degeneration
Augustin, A. J., & Kirchhof, J. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902942322 · Cited by 95 · cited 1×
“Neovascular AMD has a complex pathogenesis, which also includes a major inflammatory component.(7,8)”
BackgroundThe Role of Complement Factor H in Age-related Macular Degeneration: A Review
Donoso, L. A., Vrabec, T. R., & Kuivaniemi, H. (2010) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2009.11.001 · Cited by 92 · cited 1×
“Neovascular AMD has a complex pathogenesis, which also includes a major inflammatory component.(7,8)”
Background
Research works printed but not linked: 1
- Rosenfeld, 2006, Ranibizumab: phase III clinical trial results., Ophthalmol Clin North Am, 19, 361
Cited by
Parainflammation, Chronic Inflammation and Age-Related Macular Degeneration
Chen, M., & Xu, H. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ri0615-239r · Cited by 381
“patients [167, 168].”
Diabetic retinopathy, a vascular and inflammatory disease: Therapeutic implications
Semeraro, F., Morescalchi, F., Cancarini, A., Russo, A., Rezzola, S., & Costagliola, C. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.04.002 · Cited by 205
Nonsteroidal Anti-Inflammatory Drugs for Retinal Disease
Schoenberger, S. D., & Kim, S. J. (2013) · International Journal of Inflammation · doi:10.1155/2013/281981 · Cited by 81
Topical Nonsteroidal Anti-Inflammatory Drugs for Macular Edema
Russo, A., Costagliola, C., Delcassi, L., Parmeggiani, F., Romano, M. R., dell’Omo, R., & Semeraro, F. (2013) · Mediators of Inflammation · doi:10.1155/2013/476525 · Cited by 73
“Miyake et al. [75] prospectively compared the effects of topical diclofenac 0.1% versus fluorometholone 0.1% (a corticosteroid with limited intraocular penetration that therefore could be reasonably approximated to a placebo) in the prophylaxis of CME and reported that 5 weeks after surgery,…”
BackgroundInfluentialSystemic Vascular Safety of Ranibizumab for Age-Related Macular Degeneration
Ueta, T., Noda, Y., Toyama, T., Yamaguchi, T., & Amano, S. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.022 · Cited by 70
Metadata
- Authors
- Flaxel, C., Schain, M. B., Hamon, S. C., & Francis, P. J.
- Affiliations
- Oregon Health & Science University (US)
- Venue
- Retina
- Published
- 2012-03
- Volume
- 32
- Issue
- 3
- Pages
- 417-423
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2314031220
- Cited by
- 39
- References
- 23
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 4 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 8 · 2014: 4 · 2013: 5 · 2012: 2
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Retina (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- ranibizumab, bromfenac, neovascular age-related macular degeneration, combination therapy, intravitreal injection, eye drops, central macular thickness, visual acuity, anti-VEGF therapy
- MeSH terms
- Ranibizumab, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, Benzophenones, Bromobenzenes, Female, Humans, Macular Degeneration, Male, Middle Aged, Ophthalmic Solutions, Pilot Projects, Prospective Studies, Visual Acuity, Angiogenesis Inhibitors, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF COMBINATION RANIBIZUMAB (LUCENTIS) AND BROMFENAC (XIBROM) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Pilot Study. https://app.cochat.ai/papers/10.1097/iae.0b013e318229b0af
- The paper
- Flaxel, C., Schain, M. B., Hamon, S. C., & Francis, P. J. (2012). PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF COMBINATION RANIBIZUMAB (LUCENTIS) AND BROMFENAC (XIBROM) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Pilot Study. Retina. https://doi.org/10.1097/iae.0b013e318229b0af
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.